High blood pressure, also called hypertension, is a recognized, modifiable risk factor for dementia. Evidence links it to higher cognitive risk, especially in midlife, but does not prove that lowering blood pressure guarantees dementia prevention. Dementia has many medical, lifestyle, and environmental contributors, according to the World Health Organization. The strongest treatment trial reduced mild cognitive impairment, but it did not establish a statistically significant reduction in probable dementia alone.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What do long-term studies show?
- Did intensive treatment prevent dementia?
- Why does uncertainty remain?
- Who should pay closest attention?
- What should you do now?
What do long-term studies show?
Prospective studies follow people over time. A 2020 Journal of the American Heart Association meta-analysis combined 209 such studies. Midlife hypertension was associated with 1.19 to 1.55 times the risk of cognitive disorders, depending on the outcome examined. That category is broader than dementia.
It can include other forms of cognitive impairment, so the findings should not be read as a precise estimate of dementia risk. A 2024 Journal of Hypertension review examined 149 studies from 26 countries. Midlife hypertension was associated with poorer later-life memory, overall cognition, and executive function—the mental skills used to plan and manage tasks. These studies show a consistent relationship across large populations. They cannot predict whether one person with hypertension will develop dementia.
Did intensive treatment prevent dementia?
SPRINT MIND directly tested two treatment strategies. Participants were adults aged 50 or older who had hypertension and increased cardiovascular risk. One group targeted systolic pressure below 120 mm Hg, while the other targeted below 140. After 5.1 years, probable dementia was less frequent with intensive treatment, but the difference was not statistically significant. The hazard ratio was 0.83, with a 95% confidence interval of 0.67 to 1.04. Because that interval included 1, the trial could not rule out no difference.
The SPRINT MIND investigators reported these findings in JAMA. The trial did find a 19% reduction in mild cognitive impairment and a 15% reduction in the combined outcome of mild cognitive impairment or probable dementia. Mild cognitive impairment involves cognitive decline but is not the same outcome as probable dementia. Extended follow-up, published in Neurology in 2025, showed the same general pattern. Intensive treatment reduced mild cognitive impairment and the combined outcome, but not probable dementia alone by a statistically significant amount. For probable dementia, the hazard ratio was 0.86, with a 95% confidence interval of 0.72 to 1.02.
Why does uncertainty remain?
SPRINT did not represent everyone with hypertension. It excluded people with diabetes, a previous stroke, or dementia. Its findings therefore cannot automatically be applied to those groups. The trial also ended early and recorded fewer dementia cases than planned. That limited its ability to detect a clear difference in an outcome that may take years to emerge.
A nonsignificant dementia result does not prove that intensive treatment has no effect. It means this trial and its follow-up did not establish a dementia-prevention benefit with the required statistical certainty. WHO recommends treating hypertension under existing clinical guidelines. However, it rates the dementia-specific evidence as very low and makes its prevention recommendation conditional. Blood-pressure treatment is appropriate health care, but it should not be presented as a proven way to prevent dementia.
Who should pay closest attention?
The observational association was stronger in midlife than in late life. That makes blood-pressure control during middle adulthood especially relevant to long-term brain-health planning. For older adults, the evidence still supports taking hypertension seriously, but it does not provide a simple dementia-risk formula. Age, other health conditions, and the treatment strategy all affect how closely SPRINT applies.
Hypertension is also only one contributor to dementia risk. Having it does not make dementia inevitable, while managing it cannot remove every source of risk. A systolic target below 120 was a specific SPRINT treatment strategy, not a universal target for readers to adopt independently. This distinction is particularly important for people excluded from the trial.
What should you do now?
Blood-pressure care matters even without guaranteed dementia prevention. Hypertension is often symptomless and can cause stroke, so feeling well does not confirm that blood pressure is within an appropriate range.
Practical next steps include: WHO's hypertension fact sheet advises regular measurement, lifestyle measures, and prescribed medicines. If you already take blood-pressure medication, ask the prescriber before changing the dose or target.
- Have your blood pressure checked regularly.
- If it is high, discuss treatment under existing guidelines.
- Follow recommended lifestyle measures.
- Take prescribed blood-pressure medicines as directed.
- Do not change a medicine or treatment target solely because SPRINT tested a systolic goal below 120.
